Drugmakers on edge as pay-for-delay case hits Supreme Court

Will the U.S. Supreme Court buy pharma's argument that cash settlements don't keep generic drugs off the market unduly long? Or will the justices agree with the Federal Trade Commission, which calls such patent settlements anticompetitive? We won't know till later this year, but we'll get some hints as arguments unfold today. Report